CVS Health Q2 revenue rises 8.4% to $98.9 billion; GAAP EPS falls to $0.80
CVS Health reported second-quarter 2025 revenue of $98.9 billion, up 8.4%, but GAAP diluted EPS fell to $0.80 from $1.41 after $833 million in litigation charges. The company raised its full-year adjusted EPS guidance to $6.30 to $6.40 while cutting its GAAP EPS guidance to $3.84 to $3.94, so shareholders face a mixed picture of stronger underlying performance and lower reported profit.
Key points
- Q2 total revenues were $98.9 billion, up from $91.2 billion a year earlier; adjusted EPS was $1.81 versus $1.83
- GAAP diluted EPS guidance was revised to $3.84 to $3.94 from $4.23 to $4.43
- Adjusted EPS guidance was raised to $6.30 to $6.40 from $6.00 to $6.20
- Cash flow from operations guidance was raised to at least $7.5 billion from about $7.0 billion
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.